Eisai Bags Hong Kong Regulatory Nod For Leqembi To Treat Alzheimers

The Swedish biopharma company BioArctic AB announced that its partner Eisai has been granted approval by the Department of Health in Hong Kong for the treatment of Alzheimer's disease with Leqembi.

Patients who are in the mild cognitive impairment (MCI) or mild dementia stage of the disease, the population in which treatment was initiated in clinical trials, should begin taking Leqembi. Following the United States, Japan, China, and South Korea, Hong Kong is the fifth approval.

Leqembi's endorsement in Hong Kong depends on the enormous worldwide stage 3 Clarity AD study. In the Clarity AD study, Leqembi met its essential endpoint and all critical secondary endpoints with genuinely huge outcomes. In Hong Kong, 9.3% of people aged 70 years and older are living with dementia, and 32% of those aged and above 85 years, of whom 73.5% are reported to have Alzheimer's disease.

Leqembi reduces both Aß protofibrils and Aß plaques in the brain by binding to soluble amyloid-beta (Aß) aggregates (protofibrils) and insoluble Aß aggregates (fibrils), which are a major component of Aß plaques in AD. Leqembi is the main endorsed treatment displayed to decrease the pace of disease progression and to slow cognitive and functional downfall through this component.